Elusys Therapeutics is recruiting antibodies in its anti-terrorism campaign. The company develops antibody therapies for a variety of targets, including anthrax. Its lead product Anthim was approved by the US FDA in 2016 to treat and prevent inhaled anthrax; Elusys received federal funding for its research efforts on the drug. The company has partnered with Pfizer on another drug development program targeting Staphylococcus aureus (staph) infections, which have become increasingly prevalent and resistant to treatment. Elusys antibodies have potential applications in the treatment of additional infectious agents.